Literature DB >> 1793727

On the receiving end. IV: Validation of quality of life indicators.

P Butow1, A Coates, S Dunn, J Bernhard, C Hürny.   

Abstract

Four measures of patient functioning and a mood adjective list currently used in trials of the International Breast Cancer Study Group (IBCSG), and an 8-item Linear Analogue Self Assessment (LASA) instrument measuring specific side effects of cancer and cancer treatment (GLQ-8), were cross-validated against three established measures of quality of life, mood and psychological adjustment to cancer, in a heterogeneous sample of cancer patients. Correlations between new and established measures were high, indicating good convergent and concurrent validity. Compliance on the longer mood measures was relatively poor. Despite the difficulty in developing direct and methodologically sound measures of quality of life, the regular inclusion of practical indicators of aspects of quality of life in clinical trials would allow improved assessment of the cost-benefit ratio of treatment to outcome in cancer patients.

Entities:  

Mesh:

Year:  1991        PMID: 1793727     DOI: 10.1093/oxfordjournals.annonc.a058027

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


  24 in total

1.  Cancer chemotherapy and quality of life.

Authors:  M Byrne
Journal:  BMJ       Date:  1992-06-13

2.  Health related quality of life: a changing construct?

Authors:  Jürg Bernhard; Adam Lowy; Natascha Mathys; Richard Herrmann; Christoph Hürny
Journal:  Qual Life Res       Date:  2004-09       Impact factor: 4.147

3.  Cancer-specific geriatric assessment and quality of life: important factors in caring for older patients with aggressive B-cell lymphoma.

Authors:  Karin Ribi; Stéphanie Rondeau; Felicitas Hitz; Ulrich Mey; Milica Enoiu; Thomas Pabst; Anastasios Stathis; Natalie Fischer; Kerri M Clough-Gorr
Journal:  Support Care Cancer       Date:  2017-04-13       Impact factor: 3.603

4.  BOLD fMRI deactivation of limbic and temporal brain structures and mood enhancing effect by transcutaneous vagus nerve stimulation.

Authors:  T Kraus; K Hösl; O Kiess; A Schanze; J Kornhuber; C Forster
Journal:  J Neural Transm (Vienna)       Date:  2007-06-14       Impact factor: 3.575

5.  Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): a combined analysis of two phase 3 randomised trials.

Authors:  Jürg Bernhard; Weixiu Luo; Karin Ribi; Marco Colleoni; Harold J Burstein; Carlo Tondini; Graziella Pinotti; Simon Spazzapan; Thomas Ruhstaller; Fabio Puglisi; Lorenzo Pavesi; Vani Parmar; Meredith M Regan; Olivia Pagani; Gini F Fleming; Prudence A Francis; Karen N Price; Alan S Coates; Richard D Gelber; Aron Goldhirsch; Barbara A Walley
Journal:  Lancet Oncol       Date:  2015-06-16       Impact factor: 41.316

6.  Assessing health-related quality of life in patients with breast cancer: a reply to Maratia et al.

Authors:  Karin Ribi; Alan Coates; Lynette Blacher; Meredith M Regan; Richard D Gelber; Jürg Bernhard
Journal:  Qual Life Res       Date:  2017-09-05       Impact factor: 4.147

7.  Treatment of advanced pancreatic cancer with high-dose octreotide.

Authors:  H Friess; M Büchler; M Ebert; P Malfertheiner; H J Dennler; H G Beger
Journal:  Int J Pancreatol       Date:  1993-12

8.  The Perceived Adjustment to Chronic Illness Scale (PACIS): a global indicator of coping for operable breast cancer patients in clinical trials. Swiss Group for Clinical Cancer Research (SAKK) and the International Breast Cancer Study Group (IBCSG).

Authors:  C Hürny; J Bernhard; M Bacchi; B van Wegberg; M Tomamichel; U Spek; A Coates; M Castiglione; A Goldhirsch; H J Senn
Journal:  Support Care Cancer       Date:  1993-07       Impact factor: 3.603

9.  Estimating prognosis and palliation based on tumour marker CA 19-9 and quality of life indicators in patients with advanced pancreatic cancer receiving chemotherapy.

Authors:  J Bernhard; D Dietrich; B Glimelius; V Hess; G Bodoky; W Scheithauer; R Herrmann
Journal:  Br J Cancer       Date:  2010-09-28       Impact factor: 7.640

10.  Assessment of fatigue in cancer and non-cancer patients and in healthy individuals.

Authors:  A Glaus
Journal:  Support Care Cancer       Date:  1993-11       Impact factor: 3.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.